Navigation Links
BioDelivery Sciences to Host Conference Call and Webcast of Third Quarter 2015 Results on Monday, November 9
Date:11/2/2015

RALEIGH, N.C., Nov. 2, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its third quarter ended September 30, 2015 financial results and host a conference call and webcast at 8:00 am Eastern Time on Monday, November 9, 2015.

 Conference Call & WebcastMonday, November 9, 2015 @ 8:00 am Eastern Time Domestic:

888-510-1785International:

719-457-2664Passcode:

343795Webcast:

http://public.viavid.com/player/index.php?id=116872Replays available through November 23rd:Domestic:877-870-5176International: 

858-384-5517Conference ID:

343795


About BioDelivery Sciences International

BioDelivery Sciences International, Inc., headquartered in Raleigh, North Carolina, is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

For more information, please visit or follow us:Internet:

www.bdsi.com Facebook:

Facebook.com/BioDeliverySITwitter:

@BioDeliverySI

Cautionary Note on Forward-Looking Statements
This press release, the conference call described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentations described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the commercial launch of BUNAVAIL and the Company's clinical trials for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc  All other trademarks and tradenames are owned by their respective owners.
© 2015 BioDelivery Sciences International, Inc.  All rights reserved.

Photo - http://photos.prnewswire.com/prnh/20110217/CL49801LOGO

 


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. BioDelivery Sciences Strengthens Sales Force Leadership with Hiring of Scott Plesha, Former Salix Head of Sales
2. BioDelivery Sciences Announces Hiring of Enoch Bortey, Ph.D., as Vice President of Clinical Biostatistics and Data Systems
3. BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
4. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
5. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
6. Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility
7. Alimera Sciences To Release Third Quarter Fiscal Year 2015 Financial Results
8. Sangamo BioSciences Reports Third Quarter 2015 Financial Results
9. Axovant Sciences Announces RVT-101 Presentations at the Clinical Trials in Alzheimers Disease (CTAD) Meeting
10. SRI Biosciences Researchers Part of Team Reporting New Cancer Therapy Strategy in Nature
11. Proove Biosciences CFO Russell Skibsted Nominated CFO of the Year by the Orange County Business Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):